Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jun 09, 2021 9:36am
134 Views
Post# 33354249

RE:RE:RE:RE:Sad news

RE:RE:RE:RE:Sad newsI was not surprised - he did not look very good in the newspaper account. I actually had checked for his obituary a couple of days ago thinking it was possible he may have passed. We also sensed something was amiss early on as it seemed the second dose took longer than it should have to administer. Plus, prostate cancer was not an expected early target for TH-1902. Still, it is very sad that he TH-1902 did not turn out to be something that helped him. I am sure he and his family were hoping it might be something that would make a difference and turn the course of his disease just in time. I wish it had, perhaps for others it will. May he rest in peace and may his contributions to this trial be instrumental in helping to ultimately save others.
juniper88 wrote: This came as a shock to me, especially when you consider one of the inclusion criteria of the trial:

"Have an expected survival of at least 3 months."

 

scarlet1967 wrote: Sad, my condolences to his family and love ones, it shows how desperately these grade 3 or 4 cancer patients need a treatment.

juniper88 wrote: My condolences to his family also.  Sad news indeed.



jeffm34 wrote:

I think this might be TH's first patient in the cancer trial. Condolences to his family. 

https://www.gettysburgtimes.com/obituaries/article_cb4e3798-3083-5062-9b44-9fd624857194.html


 






<< Previous
Bullboard Posts
Next >>